No Difference in Chemotherapy Benefits for Young Patients with Stage II and III Colon Cancer Compared to Those Fifty and Older

Young patients with stage II or III colon cancer get equal benefit from chemotherapy as older patients, and they have similar side effects. Five years after treatment, 67 percent of patients under the age of fifty hadn’t had their cancer spread beyond the colon (recurrence-free interval), the same percentage that applied to patients who were fifty…  Read More

KRAS Made No Difference in Stage III Outcome

Patients with stage III colon cancer didn’t do better or worse if their tumor had mutated KRAS. Studying KRAS in the tumors of about half the patients in a large clinical trial of chemotherapy for stage III colon cancer, researchers found no differences in disease-free, recurrence-free, or overall survival.  This remained true no matter which chemotherapy…  Read More

ASCO Research Highlights: Molecular Markers in Stage II and III Colon Cancer

Several studies presented at ASCO looked a biomarkers that might predict cancer recurrence or patient survival in stage II and III colon cancer and whether patients could be chosen to receive chemotherapy based on those markers.  Of special interest was the hypothesis offered by two researchers from the PETACC-3 clinical trial that stage II and stage…  Read More

Adding Irinotecan to Infusional 5-FU Does Not Add Benefit for Stage III Colon Cancer

Five years after surgery, there was no improvement in either disease-free survival or overall survival when irinotecan was added to standard 5-FU treatments delivered via continous infusion for patients with stage III colon cancer.  Adding irinotecan increased the rate of serious side effects. The PETACC-3  (Pan European Trial Adjuvant Colon Cancer)  trial was designed to see if…  Read More